TMOD4

Across TCGA pan-cancer cohorts, TMOD4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMOD4 data layer compared with 9 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMOD4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMOD4 expression acts as an unfavorable survival marker.

HNSC, LUSC, and LIHC are the cancer types where TMOD4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.155	0.685	.013	18	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	9	view →
LIHC	OS	Median	All	0.258	0.773	.018	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TMOD4–HNSC (OS)

Open the HNSC breakdown →